2. Search Result
Search Result
Pathways Recommended: Antibody-drug Conjugate/ADC Related
Results for "

IL-23 Antibody

" in MedChemExpress (MCE) Product Catalog:

9

Inhibitors & Agonists

10

Inhibitory Antibodies

2

Antibodies

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P990217
    Anti-Mouse IL-23 p19 Antibody (G23-8)

    		Interleukin Related Others
    Anti-Mouse IL-23 p19 Antibody (G23-8) is a rat-derived IgG1, κ type antibody inhibitor, targeting to mouse IL-23 p19.
    Anti-Mouse IL-23 p19 Antibody (G23-8)
  • HY-P99256
    Tildrakizumab

    SCH 900222; MK 3222; Anti-Human IL23 Recombinant Antibody

    		 Interleukin Related Inflammation/Immunology Cancer
    Tildrakizumab (SCH 900222) is a humanized anti-IL-23 (p19 subunit) monoclonal antibody. IL-23 is a critical cytokine to maintain the Th17 cell phenotype. Tildrakizumab has high-affinity for single-chain IL-23 (Kd: 136 pM). Tildrakizumab is effective against moderate to severe plaque psoriasis .
    Tildrakizumab
  • HY-P9931
    Guselkumab

    CNTO 1959

    		 Interleukin Related Inflammation/Immunology
    Guselkumab is a recombinant human IgG1 monoclonal antibody against the IL-23p19 subunit. Guselkumab binds to human and cynomolgus monkey IL-23 with Kd values of 3.3 and 1.9 pmol/L, respectively. Guselkumab inhibits production of cytokines lying downstream of the IL-23 signaling pathway and can be used for psoriatic arthritis research .
    Guselkumab
  • HY-P99485
    Brazikumab

    AMG 139; MEDI2070

    		 Interleukin Related Inflammation/Immunology
    Brazikumab (AMG 139) is a human IgG2 monoclonal antibody, selectively binds the p19 subunit of IL-23, with a KD of 0.138 nM for human IL-23. Brazikumab can be used for the research of Crohn's disease .
    Brazikumab
  • HY-P99737
    Mirikizumab

    LY­3074828

    		 Interleukin Related Inflammation/Immunology
    Mirikizumab (LY3074828) is a humanized IgG4 monoclonal antibody that targets the p19 subunit of interleukin 23 (IL-23). Mirikizumab binds to human and monkey IL-23 with high affinity, with Kd values of 21 pM and 55 pM, respectively. By inhibiting the binding of IL-23 to IL-23R, Mirikizumab modulates the immune response and holds potential for research in ulcerative colitis and Crohn's disease .
    Mirikizumab
  • HY-P9909
    Ustekinumab
    2 Publications Verification

    Anti-Human IL-12/IL-23, Human Antibody

    		 Interleukin Related Inflammation/Immunology Cancer
    Ustekinumab is an anti-IL-12/IL-23 IgG1κ human monoclonal antibody.
    Ustekinumab
  • HY-P99248
    Risankizumab

    Risankizumab rzaa; BI 655066

    		 Interleukin Related Inflammation/Immunology
    Risankizumab (BI 655066) is a humanised IgG monoclonal antibody, targeting IL-23 p19 subunit (Kd <10 pM) and inhibiting IL-17 production induced by human IL-23 in mouse splenocytes (IC50 = 2 pM). Risankizumab can be used to research immunological and inflammatory disorders such as psoriasis vulgaris, psoriatic arthritis, generalized pustular psoriasis and erythrodermic psoriasis .
    Risankizumab
  • HY-P99486
    Briakinumab

    ABT-874

    		 Interleukin Related Inflammation/Immunology
    Briakinumab (ABT-874) is a fully human anti-IL-12/23p40 monoclonal antibody. Briakinumab targets and neutralizes IL-12 and IL-23. Briakinumab can be used for the research of rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis .
    Briakinumab
  • HY-P990057
    Picankibart

    		Interleukin Related Cancer
    Picankibart is a mouse-derived IgG1κ antibody targeting IL23A .
    Picankibart

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: